COLORADO SPRINGS, CO - (NewMediaWire) - November 11, 2015 - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its formulation and market tests are completed and Cannabis Science is set to release seven original cannabinoid-based animal care products through its wholly owned subsidiary, Equi-Pharm, LLC.
Following the recent acquisition of Equi-Pharm, LLC the Company has already expanded the company's product offerings beyond its flagship equestrian lines to include original cannabinoid-based products for other types of animals as well. With all product testing completed and such a favorable response, the Company is now diligently working to launch an e-commerce website to allow direct-to-consumer sales of these seven unique, cannabinoid-infused, animal care products. The full-featured, finished website is scheduled to launch on December 1st, 2015.
Currently, Equi-Pharm relies on its five local distributors for nearly all of its sales. They have not developed strong internet-based sales channels to date, and they have relied nearly exclusively on equestrian markets. Cannabis Science recognizes the potential in expanding total attainable market (TAM) for the company's cannabinoid-infused animal care products by expanding their product offerings to include other types of pets and creating an easy-to-use e-commerce website to drive sales. This will help reduce overhead and increase revenue generation beyond Equi-Pharm's current operations.
"This acquisition allows Cannabis Science, Inc. to leverage its expertise with the cannabinoids to create a unique niche in the pet healthcare industry, which will allow them to capture an unsaturated market segment. We are excited to roll out our new cannabinoid-based products in the U.S. and even more excited about entering the $60 billion pet healthcare industry," said Dana Kennamer, Equi-Pharm, LLC, VP of Operations.
About Equi-Pharm, LLC
Founded in 1997 in Shelbyville, TN, Equi-Pharm develops, formulates and markets horse and pet grooming aids and topical remedies using high quality ingredients in the U.S.A. The company specializes in utilizing natural ingredients to provide safe and impactful health benefits to animals. Equi-Pharm, LLC is proud to still be based in Shelbyville, TN.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.